Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:10

Sadržaj

članak: 3 od 205  
Back povratak na rezultate
2022, vol. 13, br. 1, str. 95-104
Kognitivna disfunkcija nakon hemoterapije kod žena oboljelih od karcinoma dojke
Univerzitet u Istočnom Sarajevu, Medicinski fakultet, Foča, Republika Srpska, BiH

e-adresagoricavuksanovic@gmail.com
Ključne reči: kognitivno oštećenje uzrokovano karcinomom; karcinom dojke; žene
Sažetak
Kognitivna disfunkcija povezana sa karcinomom je važan klinički problem koji može ometati svakodnevno funkcionisanje, radnu produktivnost, brigu o djeci i druge odgovornosti žena sa istorijom karcinoma dojke. Rizici od kognitivnih oštećenja povezanih sa karcinomom uključuju karcinom i liječenje karcinoma, kao i ranjivosti pacijenata. Ne postoji utvrđen standard neuroprotektivne njege ili liječenja kognitivnih oštećenja povezanih sa karcinomom dojke.
Reference
Novododat članak: provera, normiranje i linkovanje referenci u toku.
Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev 2016;25(1):16-27.
Dimitrova N, Znaor A, Agius D, Eser S, Sekerija M, Ryzhov A, et al. Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages. Eur J Cancer 2017;83:43-55.
Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DHS, et al. Cognitive complaints after breast cancer treatments: examining the relationhip with neuropsychological test performance. J Natl Cancer Inst 2013;105(11):791-801.
Lange M, Heutte N, Noal S, Rigal O, Kurtz JE, Lévy C, et al. Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer. Oncologist 2019;24(1):62-8.
Simó M, Rifà-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 2013;37(8):1311-21.
Khasraw M, Posner JB. Neurological complications of systemic cancer. Lancet Neurol 2010;9(12):1214-27.
Levitt HM. How to conduct a qualitative meta-analysis: Tailoring methods to enhance methodological integrity. Psychother Res 2018;28(3):367-78.
Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, Hayes DF, et al. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav 2017;11(1):86-97.
Kesler SR, Rao A, Blayney DW, Oakley-Girvan IA, Karuturi M, Palesh O. Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning. Front Hum Neurosci 2017;11:555.
Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HSA, Reneman L, et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One 2017;12(3):e0171724.
Kam JWY, Brenner CA, Handy TC, Boyd LA, Liu-Ambrose T, Lim HJ, et al. Sustained attention abnormalities in breast cancer survivors with cognitive deficits post chemotherapy: An electrophysiological study. Clin Neurophysiol 2016;127(1):369-78.
Berndt U, Leplow B, Schoenfeld R, Lantzsch T, Grosse R, Thomssen C. Memory and spatial cognition in breast cancer patients undergoing adjuvant endocrine therapy. Breast Care (Basel) 2016;11(4):240-6.
Chen X, He X, Tao L, Cheng H, Li J, Zhang J, et al. The attention network changes in breast cancer patients receiving neoadjuvant chemotherapy: Evidence from an arterial spin labeling perfusion study. Sci Rep 2017;7:42684.
Henneghan A, Stuifbergen A, Becker H, Kesler S, King E. Modifiable correlates of perceived cognitive function in breast cancer survivors up to 10 years after chemotherapy completion. J Cancer Surviv 2018;12(2):224-33.
Hermelink K, Bühner M, Sckopke P, Neufeld F, Kaste J, Voigt V, et al. Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. J Natl Cancer Inst 2017;109(10).
Menning S, de Ruiter MB, Kieffer JM, van Rentergem JA, Veltman DJ, Fruijtier A, et al. Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapy-Results From a Longitudinal Study. J Pain Symptom Manage 2016;52(4):560-9.e1.
Paquet L, Verma S, Collins B, Chinneck A, Bedard M, Song X. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors. Psychooncology 2018;27(1):171-7.
Ramalho M, Fontes F, Ruano L, Pereira S, Lunet N. Cognitive impairment in the first year after breast cancer diagnosis: A prospective cohort study. Breast 2017;32:173-8.
Ahles T, Root JC, Ryan EL. Cancerand Cancer Treatment-Associated Cognitive Change: An Update on the State of the Science. J Clin Oncol 2012;30(30):3675-86.
Miao H, Li J, Hu S, He X, Partridge SC, Ren J, et al. Long-term cognitive impairment of breast cancer patients after chemotherapy: A functional MRI study. Eur J Radiol 2016 85(6):1053-7.
Zheng F, Cao P, Zhou J, Li C, Norris J. Study on Neurologic and Cognitive Dysfunction in Breast Cancer Patients undergoing Chemotherapy with RS fMRI Imaging. World Neurosurg 2020;S1878-8750(20)32280-4.
Li X, Chen H, Lv Y, Chao HH, Gong L, Li CSR, et al. Diminished gray matter density mediates chemotherapy dosage-related cognitive impairment in breast cancer patients. Sci Rep 2018;8(1):13801.
Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109(1):146-56.
Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008;8(1):88-91.
Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2012;132(3):1099-106.
Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, den Stock JV, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired functioning in breast cancer patients. Hum Brain Mapp 2011;32(3):480-93.
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of highdose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 2011;33(12):2971-83.
Yoshikawa E, Matsuoka Y, Inagaki M, Nakano T, Akechi T, Kobayakawa M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005;92(1):81-4.
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res Treat 2010;123(3):819-28.
Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012;30(30):274-81.
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. J Clin Oncol 2007;25(25):3866-70.
Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011;68(11):1447-53.
Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009;15(21):6665-73.
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FSAM, Nederveen AJ, et al. Cerebral hyperresponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011;32(8):1206-19.
Silverman DHS, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007;103(3):303-11.
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during working memory processing associated with breast cancer and treatment: A prospective functional magnetic resonance imaging study. J Clin Oncol 2012;30(20):2500-8.
Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010;32(3):324-31.
Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: An fMRI study. Front Hum Neurosci 2011;5:122.
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/BII2201095V
primljen: 04.05.2022.
prihvaćen: 23.06.2022.
objavljen u SCIndeksu: 16.09.2022.

Povezani članci

Nema povezanih članaka